Reliability and Validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
Reliability and Validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
复制标题
DOI：
10.1002/art.24730
复制
发表时间：
2009-09-15
期刊：
影响因子：
--
通讯作者：
Furst, Daniel E.
中科院分区：
文献类型：
--
作者：
Khanna, Dinesh;Hays, Ron D.;Furst, Daniel E.
客观的。完善先前开发的硬皮病（系统性硬化症[SSc]）胃肠道（GIT）仪器（SSC-GIT 1.0）的方法。我们对 36 名 SSc 患者进行了 SSC-GIT 1.0 和简表； SSC-GIT 1.0 中添加了 1 个项目来评估直肠失禁。此外，受试者还完成了胃肠道受累严重程度的评级（从非常轻微到非常严重）。心理测量特性的评估包括内部一致性可靠性、重测可靠性（平均时间间隔1.1周）和多特征标度分析。结果。研究参与者主要是女性（84%）和白人（81%）； 55% 患有弥漫性 SSc。自评胃肠道受累严重程度范围从无症状到非常轻微 (39%)、轻微 (21%)、中度 (31%) 和严重/非常严重 (9%)。 SSC-GIT 1.0 最初的 53 个项目中，排除了 19 个项目，留下了 34 个项目的修订工具（加州大学洛杉矶分校硬皮病临床试验联盟 GIT 2.0 [UCLA SCTC GIT 2.01）。分析支持 7 个多项目量表：反流、腹胀/腹胀、腹泻、粪便污染、便秘、情绪健康和社会功能。重测可靠性估计值 >= 0.68，系数 alpha >= 0.67。将胃肠道疾病评为轻度的参与者在所有 7 个量表中的 0-3 级得分较低。症状量表还能够区分具有相应临床胃肠道诊断的受试者。 GIT 总分是通过对 7 个量表中的 6 个量表（不包括便秘）进行平均而得出的，该评分是可靠的，并且与单独量表相比，可以更好地区分轻度、中度和重度自评 GIT 受累。结论。这项研究为 UCLA SCTC GIT 2.0（相对于 SSC-GIT 1.0 的改进）的可靠性和有效性提供了支持，并支持 SSc 患者的 GIT 总评分。
Objective. To refine the previously developed scleroderma (systemic sclerosis [SSc]) gastrointestinal tract (GIT) instrument (SSC-GIT 1.0).Methods. We administered the SSC-GIT 1.0 and the Short Form 36 to 152 patients with SSc; 1 item was added to the SSC-GIT 1.0 to assess rectal incontinence. In addition, subjects completed a rating of the severity of their GIT involvement (from very mild to very severe). Evaluation of psychometric properties included internal consistency reliability, test-retest reliability (mean time interval 1.1 weeks), and multitrait scaling analysis.Results. Study participants were mostly women (84%) and white (81%); 55% had diffuse SSc. Self-rated severity of GIT involvement ranged from no symptoms to very mild (39%), mild (21%), moderate (31%), and severe/very severe (9%). Of an initial 53 items in the SSC-GIT 1.0, 19 items were excluded, leaving a 34-item revised instrument (the University of California, Los Angeles Scleroderma Clinical Trial Consortium GIT 2.0 [UCLA SCTC GIT 2.01). Analyses supported 7 multi-item scales: reflux, distention/bloating, diarrhea, fecal soilage, constipation, emotional well-being, and social functioning. Test-retest reliability estimates were >= 0.68 and coefficient alphas were >= 0.67. Participants who rated their GIT disease as mild had lower scores on a 0-3 scale on all 7 scales. Symptom scales were also able to discriminate subjects with corresponding clinical GIT diagnoses. The Total GIT Score, developed by averaging 6 of 7 scales (excluding constipation), was reliable and provided greater discrimination between mild, moderate, and severe self-rated GIT involvement than individual scales.Conclusion. This study provides support for the reliability and validity of the UCLA SCTC GIT 2.0, an improvement over the SSC-GIT 1.0, and supports a Total GIT Score in SSc patients with GIT.